GALAXIES Lung-301 trial: what clinicians have said so far
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
- NCT06472076 ↗
- Active, not recruiting
- GlaxoSmithKline
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on GALAXIES Lung-301 (belrestotug plus dostarlimab in previously untreated PD-L1 high non-small-cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on GALAXIES Lung-301 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X, typically up to 9 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Multicenter, Double-blind, Phase 3 Study to Investigate the Safety and Efficacy of Belrestotug in Combination With Dostarlimab Compared With Placebo in Combination With Pembrolizumab in Participants With Previously Untreated, Unresectable, Locally Advanced or Metastatic PD-L1 Selected Non-small Cell Lung Cancer (GALAXIES Lung-301)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- Dostarlimab; Belrestotug; Pembrolizumab; Placebo
- Arms
- Dostarlimab plus belrestotug · Experimental
- Pembrolizumab plus placebo · Active comparator
- Enrollment
- 88
- Primary outcomes
- Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
- Number of Participants with TEAEs or SAEs leading to dose withdrawals or treatment discontinuation
- Sponsor
- GlaxoSmithKline with iTeos Therapeutics
- Start
- Jun 10, 2024
- Primary completion
- Jun 30, 2026
- Results posted
- No
- Registry record
- NCT06472076 · updated Jul 21, 2026